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DEFINITION 
1. Caesarean section           
A birth of a fetus via laparotomy and then hysterotomy. 
 
2. Spinal anaesthesia 
A form of regional anaesthesia involving the injection of a local anaesthetic into the 
subarachnoid space. 
 
3. Postpartum hemorrhage    
Bleeding from genital tract of greater than 500 ml after vaginal delivery or blood 
loss greater than 1000ml after caesarean section.  
PPH is classified as either primary or secondary PPH. Primary PPH occurs within 
24 hours following birth while secondary PPH  occurs after 24 hours of delivery 
until 42 days postpartum.  
 
4. Parity   
Number of live born and stillbirth woman has delivered at more than 24 weeks 
gestation or birth weight more than 500g .  
Nulliparous= parity 0 
Multipara = parity 1-4 
Grandmultipara = parity ≥5 
 
5. Polyhydramnios 
Amniotic fluid index ≥ 25 cm. 
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6. Body mass index  
Weight (kg)/ height (m)² before pregnancy, categorized as : 
 Underweight BMI <18.5 
 Normal BMI 18.5-24.9 
 Overweight BMI 25-29.9 
 Obese BMI >30 
 
7. Big baby 
Clinical and ultrasound estimation of fetal weight ≥ 4kg. 
 
8. Pfannenstiel incision 
A long horizontal abdominal skin incision made below the line of the pubic hair 
and above the mons pubis, down to and through the rectus sheath. 
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ABSTRAK 
KEBERKESANAN MISOPROSTOL SEBAGAI UBAT TAMBAHAN BAGI 
OXYTOCIN SEMASA PEMBEDAHAN CAESAREAN KE ATAS WANITA YANG 
BERISIKO MENGALAMI PENDARAHAN BERLEBIHAN SEMASA DAN SELEPAS 
BERSALIN 
Dr Mudirah Mohd Yusof 
Sarjana Perubatan Obstetrik & Ginekologi 
Jabatan Obstetrik & Ginekologi 
Pusat Pengajian Sains Perubatan, Universiti Sains Malaysia, 
Kampus Kesihatan, 16150 Kelantan, Malaysia. 
 
 Pengenalan: Pembedahan Caesarean adalah merupakan salah satu prosedur 
pembedahan yang terdapat banyak komplikasi. Salah satu komplikasi yang serius adalah 
pendarahan berlebihan ketika bersalin disebabkan kegagalan rahim mengecut secara 
efektif. Misoprostol merupakan ubat yang dapat membantu pengecutan rahim dan 
menghentikan pendarahan dan boleh digunakan di dalam pembedahan. 
Objektif: Untuk menilai sama ada kombinasi misoprostol dan oxytocin lebih 
berkesan mengurangkan pendarahan semasa dan selepas bersalin secara pembedahan 
caesarean berbanding penggunaan oxytocin sahaja di kalangan wanita yang mempunyai 
faktor-faktor risiko yang diketahui untuk mengalami pendarahan berlebihan selepas 
bersalin. Untuk mengenalpasti penggunaan ubat pengecutan rahim tambahan, pemindahan 
darah atau pembedahan tambahan yang diperlukan dan mengenal pasti komplikasi dan 
kesan sampingan yang berkaitan dengan ubat-ubatan tersebut.  
xi 
 
Metodologi: Kajian prospektif berbentuk ujian rawak terkawal telah dijalankan di 
Hospital Raja Perempuan Zainab II  bermula pada Disember 2016 sehingga April 2017. 
Kajian melibatkan 156 wanita yang mempunyai faktor-faktor risiko yang diketahui untuk 
mengalami pendarahan berlebihan selepas bersalin secara pembedahan caesarean elektif. 
Mereka dibahagi secara rawak kepada 2 kumpulan untuk menerima sama ada sublingual 
misoprostol 400 mcg + IV oxytocin 5 IU bolus atau IV oxytocin 5 IU bolus sahaja selepas 
bayi dilahirkan.  Jumlah kehilangan darah semasa dan selepas pembedahan, pengurangan 
tahap haemoglobin, ubat pengecutan rahim tambahan, pemindahan darah, pembedahan 
tambahan dan kesan sampingan berkaitan dengan ubat-ubatan terapi dikenalpasti dan 
direkodkan. 
Keputusan: Seramai 156 wanita telah diambil menyertai kajian ini. Data 
demografi ibu dan faktor risiko adalah sama di  antara 2 kumpulan tersebut. Purata paras 
haemoglobin sebelum pembedahan ialah 11.3 g/dl bagi kumpulan misoprostol + oxytocin 
berbanding 11.5 g/dl bagi kumpulan oxytocin. Paras hemoglobin pesakit sebelum 
pembedahan adalah di antara 8.1-14.1 g/dl. Anggaran jumlah pendarahan semasa 
pembedahan  bagi kumpulan oxytocin adalah lebih banyak dari kumpulan misoprostol + 
oxytocin (654.5 ml±259.9 berbanding 524.3 ml±253.9, p= 0.010). Anggaran jumlah 
pendarahan selepas pembedahan bagi kumpulan oxytocin adalah statistik lebih tinggi dari 
kumpulan misoprostol + oxytocin (90 ml±29.6 versus 77.1 ml±23.7, p= 0.003). Ia juga 
menunjukkan  bilangan pendarahan berlebihan  yang dilihat dalam kumpulan oxytocin 
lebih tinggi berbanding kumpulan misoprostol + oxytocin  (19(24.4%) versus 9(11.5%), p 
= 0.037). Insiden Pendarahan berlebihan dalam kajian ini ialah 17.9%. Daripada 19 pesakit 
yang mengalami pendarahan berlebihan dalam kumpulan oxytocin, 7 (36.8%) pesakit telah 
diberi satu suntikan hemabate  250mcg berbanding kumpulan misoprostol+oxytocin, hanya 
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2 (22.2%) pesakit memerlukan satu suntikan hemabate 250mcg.  Hanya 4 pesakit yang 
mengalami pendarahan berlebihan memerlukan pemindahan darah.  
Kesimpulan: Kombinasi sublingual misoprostol dan oxytocin lebih banyak 
mengurangkan kehilangan darah semasa dan selepas bersalin secara pembedahan 
caesarean berbanding oxytocin sahaja di kalangan wanita yang mempunyai faktor-faktor 
risiko pendarahan berlebihan semasa dan selepas pembedahan caesarean. Ia juga selamat 
untuk digunakan. Oleh yang demikian misoprostol harus dianggap sebagai alternatif yang 
baik untuk ubat pengecutan rahim lain dalam mengelakkan pendarahan berlebihan semasa 
dan selepas pembedahan bersalin. 
 
Professor Dr Nik Mohamed Zaki Nik Mahmood: Supervisor  
Dr Zainal Abidin Hanafiah: Co-Supervisor 
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ABSTRACT 
EFFECT OF MISOPROSTOL AS AN ADJUNCT TO OXYTOCIN DURING 
CAESAREAN DELIVERY IN WOMEN AT RISK OF POSTPARTUM HEMORRHAGE 
Dr Mudirah Mohd Yusof 
MMED Obstetrics & Gynaecology 
Department of Obstetrics & Gynaecology 
School of Medical Sciences, Universiti Sains Malaysia, 
Health Campus, 16150 Kelantan, Malaysia. 
 
 Introduction: The caesarean section was a recognized risk factor for PPH. The 
common cause of PPH during caesarean delivery includes uterine atony result in 
complications including both maternal and fetal morbidity and mortality. Oxytocin is the 
first choice of uterotonic agent for prevention of PPH during caesarean delivery. The use 
of additional uterotonic agent is common in women with known risk factor for PPH. 
Misoprostol has been evaluated as an alternative to oxytocin and has also been used in 
combination with oxytocin. 
Objectives: To evaluate whether a combination of misoprostol and oxytocin more 
effectively reduces blood loss during and after caesarean delivery than does oxytocin alone 
among women with  known risk factors for postpartum hemorrhage. To document the use 
of additional uterotonic drugs, the need of blood transfusion or additional surgical 
intervention for PPH and to identify the complication and adverse effects related to drugs 
therapy. 
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Methodology: A prospective single blinded randomised control trial was 
conducted in Hospital Raja Perempuan Zainab II from December 2016 until April 2017. 
The study included 156 women with known risk factor for PPH undergoing elective 
caesarean section under spinal anaesthesia. They were assigned randomly into 2 groups to 
receive either sublingual misoprostol 400mcg+ IV oxytocin 5 IU bolus or IV oxytocin 5 IU 
bolus just after delivery of baby.  The outcome measures were intraoperative and 
postoprerative blood loss, reduction in haemoglobin, additional uterotonic agents, blood 
transfusion, additional surgical intervention for PPH and adverse effects relate to drugs 
therapy.   
Results: A total of 156 women were recruited and completed this study. The 
maternal demographic data and risk factors were similar between the 2 groups.  The mean 
for preoperative haemoglobin was 11.3 g/dl in misoprostol+oxytocin group compared to 
11.5 g/dl in oxytocin group. The range of preoperative haemoglobin was 8.1-14.1 g/dl. The 
estimated blood loss intraoperatively in oxytocin group was statistically significantly 
higher than the misoprostol+oxytocin group (654.5 ml±259.9 versus 524.3ml±253.9, p = 
0.010). Estimated blood loss postoperatively in oxytocin group was statistically 
significantly higher than the misoprostol+oxytocin group (90 ml±29.6 versus 77.1 
ml±23.7, p =0.003). It also showed statistically significant higher number of PPH seen in 
oxytocin group compared to misoprostol+oxytocin group (19(24.4%) versus 9(11.5%), p= 
0.037). The incidence of PPH in this study was 17.9%. Out of 19 patient with PPH in 
oxytocin group, 7 (36.8%) patients required additional single dose IM hemabate 250 mcg  
compared to misoprostol group,  only 2 (22.2%) patients required single dose IM hemabate 
250mcg.  Only 4 patients with PPH required blood transfusion. However, no significant 
difference was demonstrated between the 2 groups in term of reduction in hemoglobin 
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level (p=0.750), any additional uterotonic drug (p=0.083) and blood transfusion (p=0.310). 
No additional surgical intervention required for both groups. 
Conclusion: Combination of sublingual misoprostol and oxytocin more effectively 
reduces blood loss during and after caesarean delivery than does oxytocin alone among 
women with risk factors for PPH.  It also appears safe and well tolerated in this population. 
Therefore misoprostol should be considered as a good alternative to other uterotonics in 
prevention of PPH following caesarean delivery. 
 
Professor Dr Nik Mohamed Zaki Nik Mahmood: Supervisor  
Dr Zainal Abidin Hanafiah: Co-Supervisor 
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1.0 INTRODUCTION 
1.1 CAESAREAN DELIVERY 
 
Caesarean delivery defines as a birth of a fetus via laparotomy and then hysterotomy 
(Cunningham et al, 2014).  It is one of the commonest surgical procedures performed in 
obstetric practice.  
 
The number of CS has been rising tremendously over the years due to various 
indications. This surgical procedure has been proven to result in complications, 
including both maternal and fetal morbidity and mortality. Complications include post 
partum hemorrhage (PPH), visceral injury, extended tear resulting in broad ligament 
hematoma, the need for blood transfusion, infection and venous thromboembolism. 
Long term complications include placenta previa and placenta accreta. Fortunately, 
some of the complications can be minimized by proper pre operative assessment, 
appropriate indications, performed by skilled doctors and measurements taken prior to 
or during operative procedures. 
 
Caesarean section rate is defined as the total number of caesarean deliveries over the 
total number of deliveries, and is usually expressed in percentage. The global CS rate 
was estimated around 15%, but higher in developed countries such as Latin America 
and Caribbean, but lower in other developing countries (Betran AP et al., 2007). In 
Asia, the CS rate was 15.9% and more specifically in South East Asia, the rate was 
6.8%. In Malaysia, the CS rates have been gradually increasing in trend. The caesarean 
section rate in Malaysian public hospitals has increased to 15.7% (in 2006) from 10.5% 
in the year 2000 (Ravindran J, 2006). The CS rate from the 14 tertiary hospitals in 
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Malaysia was 23.08% in 2010 (Sharmala Devi Karalasingam et al., 2010). The study 
also reported 18.71% of patients were delivered via caesarean section in Hospital Raja 
Perempuan Zainab II Kota Bharu, Kelantan.  
 
1.2 POSTPARTUM HEMORRHAGE 
 
Obstetric hemorrhage is one of the leading causes of preventable maternal mortality and 
accounts for 25% of maternal deaths in developing country (Mukherjee S et al., 2009).  
The risk of developing PPH has been estimated around 1 in 1000 deliveries (Drief J, 
1997). The incidence of PPH affects approximately 2% of all women who give birth 
(WHO, 2012).  
 
Post partum hemorrhage is defined as bleeding from genital tract of 500ml or more after 
vaginal delivery, or greater than 1000ml after caesarean section, or any blood loss 
sufficient enough to cause haemodynamic instability in postpartum patient (MOH 
Malaysia, 2016).  Bleeding is considered major once the blood loss is 1000ml or more 
(Mavrides E et al., 2016).  
 
PPH can be further divided into primary and secondary PPH. Primary PPH occurs 
within 24 hours following birth, while secondary PPH reflects to any abnormal bleeding 
from the birth canal which happens after 24 hours of delivery till 42 days postpartum.   
 
PPH is associated with high risk of morbidity and mortality to the mother. Catastrophic 
bleeding will lead to coagulopathy, hysterectomy, renal failure, cardio respiratory 
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collapsed, complications from  massive blood transfusion and intensive care admission 
(Devine, 2009). 
 
Maternal mortality rate (MMR) is the number of women who died from any cause 
related to or aggravated by pregnancy or its management (excluding accidental or 
incidental causes) during pregnancy or childbirth or within 42 days of termination of 
pregnancy, irrespective of the duration of pregnancy, per 100,000 live births.  
 
According to the report produced by Kaur J et al (2011), the common causes of MMR 
were the direct causes, including PPH (17.4%), obstetric thromboembolism (17.4%) and 
hypertensive disorders in pregnancy (18.1%).  Of the 14 million women who have PPH 
each year, about 2% die, with an average interval from onset of bleeding to death of 2 to 
4 hours (Abou Zahr, 1998). Since the introduction of the Millennium Development Goal 
5 (MDG 5) to our setting in 1990, the incidence of maternal mortality has reduced due 
to the implementation of comprehensive strategies. The main objective of MDG 5 is to 
achieve a reduction of MMR by three quarters (11 per 100,000 populations) from 1990-
2015.  
 
The main causes of PPH are the ‘4 Ts’ which includes tone (70%), trauma (20%), tissue 
(10%) and thrombin (<1%) (MOH Malaysia, 2016). Table 1.1 showed summary of 
common causes and risk factors of PPH. 
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Table 1.1: The causes of PPH (Mavrides E et al, 2016) 
The four Ts Risk factors/notes 
Tone: abnormalities of uterine contraction. 
Overdistension of uterus. 
 
Intra-amniotic  infection. 
Functional/anatomic distortion of uterus. 
 
Uterine relaxants.   
 
Bladder distension. 
 
Polyhydramnios, multiple gestation, 
macrosomia. 
 
Fever, prolonged rupture of membranes. 
Rapid labour, prolonged labour, fibroids, 
placenta praevia, uterine anomalies. 
 
 
Magnesium and nifedipine Terbutaline, 
halogenated anaesthetics, glyceryl 
trinitrate. 
 
May prevent uterine contraction. 
Tissue: retained products of conception. 
Retained cotyledon or succenturiate lobe. 
Retained blood clots. 
 
Trauma: genital tract injury. 
Lacerations of the cervix, vagina or 
perineum. 
 
Extensions, lacerations at caesarean 
section. 
 
Uterine rupture.  
Uterine inversion. 
 
Precipitous delivery, operative delivery. 
 
 
Malposition, deep engagement. 
 
 
Previous uterine surgery. 
 
High parity with excessive cord traction. 
Thrombin: abnormalities of coagulation 
Pre-existing states:  
 
Acquired in pregnancy. 
 
 
Haemophilia A.  
Idiopathic thrombocytopenic purpura. 
von Willebrand’s disease. 
 
Gestational thrombocytopenic.  
Pre-eclampsia with thrombocytopenia 
(HELLP). 
 
6 
 
Disseminated intravascular coagulation.  
 
 
 
Therapeutic anticoagulation. 
History of previous PPH. 
 
a) Gestational hypertensive disorder of 
pregnancy with  coagulopathy.  
b) in utero fetal demise. 
c) severe infection.  
d) abruption. 
e) amniotic fluid embolus.  
 
 
History of thromboembolic disease. 
 
 
 
The common causes of PPH during cesarean delivery include uterine atony, bleeding 
from the uterine incision or extensions of this incision and placenta 
accreta/increta/percreta. Uterine atony can be isolated or associated with one or more of 
the other causes of hemorrhage. Cervical and vaginal lacerations typically occur during 
cesarean delivery when the operator attempts to dislodge a fetal head wedged deep in 
the pelvis. Serious hemorrhage from the uterine incision is generally caused by lateral 
extension, which can result from excessive traction when creating the incision or from 
tears resulting from delivery of the fetus through an incision that is too small (Allan J 
Jacobs, 2011) 
 
The caesarean section was a recognized risk factor for PPH. Briley et al (2014) 
demonstrated how prepregnancy and pregnancy-acquired factors may be mediated 
through intrapartum events, including caesarean section, elective (aOR 24.4, 95% CI 
5.53-108.00) or emergency (aOR 40.5, 95% CI 16.30-101.00), and retained placenta 
(aOR 21.3, 95% CI 8.31-54.7) which increased the incidence of postpartum 
haemorrhage.  
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Prevention of postpartum haemorrhage begins early in high risk women, as early as in 
preconception period. Prevention and optimization of anemia allows better tolerability 
to variable severity of PPH. WHO defined anaemia in pregnancy as haemoglobin level 
below 11 g/dl. It divided into mild (Hb 10.0-10.9 g/dl), moderate (Hb 7.0-9.9 g/dl) or 
severe anaemia (<7.0 g/dl). Hb <9.0 g/dl was associated with greater blood loss (90.6 
ml , p <0.01) average at delivery and 24 hours postpartum period  compared to 
nonanaemic women ( Kavle JA et al, 2008). Iron deficiency anaemia is the commonest 
cause of anaemia in pregnancy. Treatment with oral iron reduces the incidence of 
anaemia (RR 0.38 95% CI 0.26-0.55) (Reveiz et al, 2007).  
 
The use of oxytocin and cord traction is the recommended method to prevent PPH in 
caesarean section (WHO,2012). Oxytocin is the first choice of uterotonic agent for 
prevention of PPH during caesarean delivery. It is as effective as ergot alkaloids or 
prostaglandins and has fewer side effects (Janice M Anderson 2007, Mc Donald S et al 
2004, Gulmezoglu AM 2004).  
 
Uterine atony is responsible for most cases of PPH about 70%. The majority of these 
could be avoided through the use of prophylactic uterotonics drugs during the third 
stage of labour and in conjunction with uterine massage.  Prophylactic administration of 
oxytocin reduces rates of postpartum hemorrhage by 40%.  
 
1.3 OXYTOCIN 
 
Oxytocin (Pitocin®, Syntocinon®) is a sterile, clear, colorless aqueous solution that 
contains 10 units of oxytocin /mL in 1 ampoule. Oxytocin stimulates the upper segment 
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of the myometrium to contract rhythmically following delivery, constricting spiral 
arteries and decreasing blood flow through the uterus. It is used for prevention as well 
as treatment of PPH. 
 
The study by Mc Donald S et al (2004) involved 9332 women reported that 
syntometrine, oxytocin 5 IU and oxytocin 10 IU have similar efficacy in preventing 
PPH in excess of 1000ml.  5 IU oxytocin by slow bolus IV injection is currently 
recommended for all caesarean section ( MOH Malaysia 2016, Mavrides E et al 2016).  
 
The combination of an oxytocin infusion after an initial IV bolus of oxytocin after 
caesarean delivery reduces the need for additional uterotonic agents but does not affect 
the overall occurrence of major obstetric haemorrhage (WHO, 2012).  
 
Oxytocin can be administered via intravenous or intramuscular route. The onset of 
action depends on the route of administration. It has rapid immediate onset of action via 
intravenous compare to intramuscular administration (within 3-5 minutes). The peak 
concentration is within 40 minutes. Oxytocin has a plasma half-life of about 1 to 6 
minutes.  Following intravenous administration of oxytocin, uterine response subsides 
within 1 hour compare to intramuscular injection the uterine response persists for 2 to 3 
hours. It has rapid excretion largely by the kidney and the liver. Only small amounts are 
excreted in urine unchanged.  
 
The side effects include transient vasodilatation and hypotension, nausea, vomiting and 
painful contraction. Overdose or prolonged use of oxytocin infusion for >24 hours can 
cause water intoxication.  
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1.4 MISOPROSTOL. 
 
The use of additional uterotonic agent is common in women with known risk factor for 
PPH. Misoprostol has been evaluated as an alternative to oxytocin and has also been 
used in combination with oxytocin. 
 
The usefulness of misoprostol, a synthetic prostaglandin E1 analog marketed for the 
prevention and/or treatment of peptic ulcers, in the active management of the third stage 
of labour in developing countries was first reported by El-Refaey in 1996. Misoprostol 
is an effective myometrial uterine stimulant, selectively binding to EP-2/EP-3 
prostanoid receptors. Because of its uterotonic effects, misoprostol has been 
demonstrated to be effective for both the prevention and treatment of PPH. Misoprostol 
is the cheapest uterotonic drugs and requires no refrigeration or syringe. With its ease of 
administration and storage, there has been increasing evaluation and promotion of 
misoprostol in developing countries. 
 
Misoprostol can be administered via sublingual, oral, vaginal and per rectal. Compared 
with other routes of administration, sublingual and oral misoprostol is rapidly and 
almost completely absorbed from the gastrointestinal tract. The misoprostol tablet is 
very soluble and can dissolve in 20 minutes when it put under the tongue. Sublingual 
misoprostol has the shortest time to peak concentration, the highest peak concentration 
and the greatest bioavailability when compared to other routes. The avoidance of first-
pass metabolism via the liver achieves a higher peak concentration by sublingual 
administration. Following a single dose of 400 mcg sublingual misoprostol, the plasma 
misoprostol level increases rapidly, onset of action within 8-11 minutes and peaks at 
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about 30 minutes, decline by 120minutes after administration (O.S. Tang et al, 2007). 
This characteristic makes sublingual misoprostol more suitable than other routes of 
administration for clinical applications requiring a rapid onset of action, such as that 
required for the prevention of PPH.  
 
Misoprostol generally is well tolerated. The frequency of side effects does not appear to 
be affected by patient age in adults. The most common side effects associated with 
misoprostol involve the gastrointestinal tract (e.g., diarrhea, nausea, vomiting and   
abdominal pain). Less common or rare side effect include bleeding from vagina, 
constipation, cramps in lower abdomen or stomach area, gas, headache, heartburn and 
indigestion. Symptoms of overdose include convulsions (seizures), drowsiness, fast or 
pounding heartbeat, fever, low blood pressure, tremor and troubled breathing. 
 
There are limited research on the optimal dose, route of admission and efficacy done for 
patient with known risk factors for PPH in Malaysia. Therefore the purpose of this study 
will contribute to produce more local data for decision and use of misoprostol for high 
risk patient to prevent postpartum hemorrhage. Hopefully the knowledge will be 
valuable and give benefit to patient, hospital care and country.    
 
Cost savings could also be gained from avoiding the use of additional uterotonic drugs 
such as carboprost, carbetocin and also expensive haematological agents such as Factor 
VIIa, which are establishing its place in the treatment of massive PPH in modern 
obstetrics despite extreme costs.  
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2.0 LITERATURE REVIEW 
 
Many risk factors for PPH have been reported. A study including 154,311 deliveries 
compared 666 cases of PPH to controls without hemorrhage by Sheiner E et al (2005)    
found that factors significantly associated with hemorrhage include retained 
placenta/membranes (odds ratio [OR] 3.5, 95% CI 2.1-5.8), failure to progress during 
the second stage of labor (OR 3.4, 95% CI 2.4-4.7), morbidly adherent placenta (OR 
3.3, 95% CI 1.7-6.4), lacerations (OR 2.4, 95% CI 2.0-2.8), instrumental delivery (OR 
2.3, 95% CI 1.6-3.4), large for gestational age newborn ( >4000 g) (OR 1.9, 95% CI 
1.6-2.4), hypertensive disorders (preeclampsia, eclampsia, HELLP [Hemolysis, 
Elevated Liver enzymes, Low Platelets] syndrome) (OR 1.7, 95% CI 1.2-2.1), induction 
of labor (OR 1.4, 95% CI 1.1-1.7) and prolonged first or second stage of labor (OR 1.4, 
95% CI 1.2-1.7). 
 
In another large series study by Mhyre JM et al (2013), the most common risk factors 
associated with need for massive transfusion during hospitalization for delivery were 
abnormal placentation (1.6/10,000 deliveries, adjusted OR [aOR] 18.5, 95% CI 14.7-
23.3), placental abruption (1.0/10,000, aOR 14.6, 95% CI 11.2-19.0), severe 
preeclampsia (0.8/10,000, aOR 10.4, 95% CI 7.7-14.2), and intrauterine fetal demise 
(0.7/10,000, aOR 5.5, 95% CI 3.9-7.8). 
 
Other risk factors include personal or family history of previous PPH, obesity, high 
parity, Asian or Hispanic race, precipitous labour, uterine over distention (e.g: multiple 
gestation, polyhydramnios, macrosomia), uterine infection, uterine inversion, inherited 
bleeding diathesis, acquired bleeding diathesis (e.g: amniotic fluid embolism, abruptio 
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placenta, sepsis, fetal demise), and use of some drugs such as uterine relaxants and 
drugs that affect coagulation (possibly including antidepressants) (Bateman BT et al 
2010, Cheng YW et al 2009, Wetta LA et al 2013, Kramer MS et al 2013, Sharp GC et 
al 2014, Bruning AH et al 2015, Oberg AS et al 2014, Giannella L et al 2013). 
 
In postpartum hemorrhage, treatment can be divided into pharmacological (uterotonic 
drugs/ prostaglandins), mechanical methods (tamponade balloon) and surgical methods. 
Studies have shown that active management of third stage of labour reduces blood loss 
and risk of PPH. Four Cochrane reviews addressed prophylaxis in the third stage of 
labour in women delivering vaginally. The Active Versus Expectant Management in the 
Third Stage of Labour included five trials and found that active management (which 
includes the use of uterotonic drugs, early cord clamping, and controlled cord traction) 
was associated with lower maternal blood loss with reduced risks of PPH and prolonged 
third stage (Mousa HA et al, 2007).  
 
Active management of third stage of labour reduces the risk of PPH by 60% 
(Prendiville WJ et al, 1988), the need of blood transfusion (McCormick M.L et al, 
2002) and subsequently maternal morbidity and mortaliy (WHO 2012). Oxytocin and 
other prostaglandins have been used in prevention of PPH. Four randomized control 
trials have compared different uterotonic drugs for prophylaxis in women delivering via 
Caesarean Section, and recommended 5 IU oxytocin via slow bolus intravenous 
injection (Mavrides E et al, 2016). A longer acting oxytocin derivative, Carbetocin is 
licensed in the UK specifically for the indication of prevention of PPH in the context of 
caesarean delivery. Randomized controlled trial suggested that a single dose of 
carbetocin 100mcg is at least as effective as oxytocin by infusion (Dansereau J et al, 
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2006). However it has not been recommended for routine use due to the paucity of data 
and its high price.   
 
Misoprostol is being advocated for wide use in prevention and treatment of PPH, and is 
recommended for such in certain settings by the World Health Organization, the 
Clinical Practice Obstetrics Committee; Society of Obstetricians and Gynecologists of 
Canada (Leduc 2009) and the American College of Obstetricians and Gynecologists 
(ACOG 2006). The Royal College of Obstetricians and Gynecologists Green-Top 
Guideline no 52 of 2009 (revised 2011)  recommends misoprostol 1000 mcg rectally for 
treatment of PPH when other interventions fail (RCOG 2009). Guidance for the use of 
misoprostol for the prevention (FIGO 2012a) and treatment (FIGO 2012b) of PPH has 
been issued by the International Federation of Gynecology and Obstetrics. 
 
A paper published in Cochrane Database Systemic Review title Prostaglandin for 
preventing postpartum hemorrhage conducted by Tuncalp O et al (2012) included 72 
trials (52,678 women). Oral or sublingual misoprostol compared with placebo is 
effective in reducing severe PPH (blood loss>1000 ml). Seven trials involved  6225 
women with oral misoprostol not totalled due to significant heterogeneity. One trial 
involving 661 women with sublingual misoprostol noted RR 0.66; 95% CI 0.45- 0.98. 
Need for blood transfusion (oral: RR 0.31; 95% CI 0.10-0.94; four trials, 3519 
women).Compared with conventional injectable uterotonics, oral misoprostol was 
associated with higher risk of severe PPH (RR 1.33; 95% CI 1.16- 1.52; 17 trials, 
29,797 women) and use of additional uterotonics, but with a trend to fewer blood 
transfusions (RR 0.84; 95% CI 0.66 to 1.06; 15 trials; 28,213 women). Additional 
uterotonic data were not totalled due to heterogeneity. Misoprostol use is associated 
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with significant increases in shivering and a temperature of 38º C compared with both 
placebo and other uterotonic. Therefore an injectable uterotonic is the drug of choice for 
routine third stage management when the placenta is delivered. Oral or sublingual 
misoprostol may be used where no injectable uterotonic is available. 
 
A double blind randomised controlled trial study conducted by Bellad MB et al (2012) 
involved a total of 652 patients, compared the postpartum measured blood loss with 400 
mcg sublingual misoprostol and after standard care using 10 IU intramuscular (IM) 
oxytocin. The mean blood loss with sublingual misoprostol was 192 +/- 124 ml (n = 
321) and 366 +/- 136 ml with oxytocin IM (n = 331, P <= 0.001). The incidence of PPH 
(blood loss >500ml) was 3.1% with misoprostol and 9.1% with oxytocin (p = 0.002). 
No woman lost >=1000 ml of blood. 9.7% and 45.6% of women experienced a 
haemoglobin decline of >10% after receiving misoprostol and oxytocin (p < 0.001). 
Side effects were significantly greater in the misoprostol group than in the oxytocin 
group. This study demonstrated Sublingual misoprostol is more effective than 
intramuscular oxytocin in reducing PPH, with only transient side effects being greater in 
the misoprostol group.  
 
A paper published in International Journal Gynaecology Obstetrics by P. Chaudhuri et 
al (2010) title rectally administered misoprostol versus intravenous oxytocin infusion 
during cesarean delivery to reduce intraoperative and postoperative blood loss. They 
compare the efficacy of rectally administered misoprostol with intravenous oxytocin 
infusion in preventing uterine atony and blood loss during cesarean delivery. 200 
women undergoing cesarean delivery who did not have risk factors for postpartum 
hemorrhage were randomly allocated to receive either 800 µg of rectal misoprostol or 
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an intravenous infusion of oxytocin. A total of 96 and 94 women were analyzed in the 
misoprostol and oxytocin groups, respectively. Intraoperative and postoperative blood 
loss was significantly lower in the misoprostol group than in the oxytocin group (503 vs 
592 ml, p = 0.003 and 74 vs 114 ml, p = 0.045, respectively). The incidence of shivering 
was higher in the misoprostol group (8.3% vs 1.1%, p= 0.018; RR 7.83; 95% CI 0.99–
61.42).  However the difference of intraoperative blood loss between 2 groups was only 
89ml and postoperative blood loss was only 40 ml, although statistically significant. 
Therefore rectal misoprostol appears to be an effective alternative to intravenous 
oxytocin in preventing blood loss for routine use during cesarean delivery.  
 
Another prospective, randomized, double-blind, placebo-controlled trial was performed 
at a tertiary care centre in Kolkata, India by P. Chaudhuri  and Majumdar A (2014) to 
evaluate whether a combination of misoprostol and oxytocin more effectively reduces 
blood loss during and after caesarean delivery than does oxytocin alone among women 
with known risk factors for PPH. Both groups contained 198 women. Mean 
intraoperative blood loss was significantly lower in the misoprostol group (505.4±215.5 
ml) than in the placebo group (587.3±201.5 ml; P<0.001). Mean postoperative blood 
loss was slightly lower in the misoprostol group (96.9±57.3 ml) than in the placebo 
group (103.4±58.4 ml; P=0.07). Shivering and pyrexia were more frequently associated 
with misoprostol (P<0.05 for both). They concluded that misoprostol as an adjunct to 
oxytocin seemed to more effectively reduce blood loss than did oxytocin alone. 
However the difference of intraoperative blood loss between 2 groups was only 82ml 
and postoperative blood loss was only 6ml, although statistically significant. Therefore 
misoprostol+oxytocin group was having similar outcome compared to oxytocin only 
group.  
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Another  prospective double-blind randomized clinical trial study conducted by Pakniat 
H Khezri (2015) to compare the effect of combined oxytocin-misoprostol versus 
oxytocin and misoprostol alone in reducing blood loss at caesarean delivery showed that 
the mean blood loss during surgery was significantly lower in group  oxytocin-
misoprostol (received 200-mcg misoprostol plus 5 IU bolus intravenous oxytocin, group 
MO)  compared to other groups (P = 0.04) ( received 20 IU infusion of oxytocin , group 
O) or 400-mcg sublingual misoprostol tablets , group M).  The use of combined lower 
dose of misoprostol-oxytocin significantly reduced the amount of blood loss during and 
after the lower segment caesarean section compared to higher dose of oxytocin and 
misoprostol alone, and its use was not associated with any serious side effects. 
 
A randomized controlled trial to look for the effect of sublingual misoprostol versus 
intravenous oxytocin on reducing blood loss at cesarean section in Nigeria by K.M. 
Owonikoko et al (2011) involved 100 women with term singleton pregnancy 
undergoing elective or emergency cesarean section under spinal anesthesia. They 
compare the effectiveness and safety of sublingual misoprostol with i.v. oxytocin 
infusion administered after delivery in reducing blood loss at cesarean section in 
Nigeria. One hundred women in Nigeria were randomly allocated to receive either 
misoprostol 400 mcg sublingually or i.v. infusion of 20 units oxytocin soon after 
delivery of the baby. Estimated blood loss at surgery and within the first 4 h post-
operation were measured in both groups. No significant difference was found in mean 
blood loss between the oxytocin and misoprostol groups. Similarly, no significant 
difference occurred between preoperative and postoperative hematocrit levels and need 
for additional oxytocin in both groups. There was significantly less blood loss in the 
first 4 h after surgery in the misoprostol group than in the oxytocin group (58.2 ± 20.7 
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vs 80.5 ± 26.8; P-value = 0.02).  However the difference of blood loss amount was 
small and only 22ml. The incidence of adverse effects like shivering/pyrexia was 
significantly higher in the misoprostol group than in the oxytocin group (27/50 vs 1/50, 
P < 0.001). Therefore sublingual misoprostol was as effective as i.v. oxytocin infusion 
in reducing blood loss at cesarean section. It offers several advantages over oxytocin, 
including long shelf life, stability at room temperature, and oral administration, which 
make it a suitable uterotonic agent in low-resource areas.  
 
A study by N. Eftekhari et al (2009) title the effect of sublingual misoprostol versus 
intravenous oxytocin in reducing bleeding after caesarean section was conducted in 100 
singleton pregnant women underwent a caesarean delivery under general anaesthesia. 
Patients were randomly divided into two equal groups. One group received two tablets 
of misoprostol 200 μg sublingually and the second group took intravenous infusion of 
20 units of oxytocin at the rate of 10 ml/min immediately after delivery until full 
contraction of the uterine. The amount of blood loss was lower in misoprostol group 
comparing with oxytocin group (608.91 ml vs 673.9 ml, p= 0.048) and this difference 
was statistically significant. The need to give additional oxytocin therapy in oxytocin 
group (36) was significantly higher than misoprostol group (14, p 0.032). It seems that 
the efficacy of sublingual misoprostol is equivalent to that of low dose intravenous 
oxytocin in reducing postpartum haemorrhage at caesarean section. Misoprostol has 
some other advantages like long shelf -life, stability at room temperature and oral use. 
 
Another previous study by N. Vimala et al (2006) to compare the effectiveness of 400 
mcg sublingual misoprostol administered immediately after delivery of the neonate at 
cesarean section, with 20 units intravenous oxytocin infusion in prevention of uterine 
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atony and thereby reducing blood loss at cesarean section. One hundred women with 
singleton term pregnancy undergoing elective or emergency lower segment cesarean 
section under spinal anesthesia were included in this study. The mean blood loss 
estimated was significantly lower in misoprostol group compared to oxytocin group 
(819 ml versus 974 ml; p = 0.004). The number of women who had blood loss 
exceeding 500 ml and the change in hemoglobin, however, was comparable between the 
two groups. There was a need for additional oxytocic therapy in 16% and 18% after use 
of misoprostol and oxytocin respectively (p = 0.673). The incidence of side effects such 
as pyrexia, shivering and metallic taste was significantly higher in misoprostol group 
compared to oxytocin group. The sublingual misoprostol appears to be as effective as 
intravenous infusion of oxytocin in reducing blood loss at cesarean section.  
 
J. Hamm et al (2005) did a randomized study regarding buccal misoprostol to prevent 
hemorrhage at cesarean delivery. A total of 352 patients who underwent cesarean 
delivery were assigned randomly to either 200-μg misoprostol or placebo placed in the 
buccal space. A dilute intravenous oxytocin infusion was given to all patients at 
delivery of the placenta. The mean estimated blood loss between the misoprostol and 
placebo groups was 749± 173 ml versus 725±212 ml, respectively (p 0.250). More 
women in the placebo group required 1 additional uterotonic agent (76/179 women 
[43%] vs 45/173 women [26%]; p 0.010; relative risk, 1.3; 95% CI, 1.10-1.50). There 
were no differences between the groups in the incidence of maternal adverse 
events.There was not a difference between the groups in the incidence of postpartum 
hemorrhage or a difference in preoperative and postoperative hemoglobin level. Buccal 
misoprostol reduces the need for additional uterotonic agents during cesarean delivery. 
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3.0 OBJECTIVES 
3.1 General and specific objectives 
 
General Objective 
To study whether a combination of misoprostol and oxytocin more effectively reduces 
blood loss during and after caesarean delivery than does oxytocin alone among women 
with  known risk factors for postpartum hemorrhage. 
 
Specific Objectives 
a) To determine proportion of postpartum  hemorrhage among women with    
known risk factor in both groups. 
b) To compare the amount of blood loss during intraoperative and 
postoperative periods between control and study groups. 
c) To determine the need for additional uterotonic drugs (within 24 hours), 
blood transfusion (until discharge) or additional surgical intervention need 
for primary PPH (within 24 hours) between control and study groups. 
d) To identify the complication and adverse effects related to drugs therapy  
(within 24 hours). 
 
3.2 Study hypothesis 
Combination of misoprostol and oxytocin more effectively reduces blood loss during 
and after caesarean delivery than does oxytocin alone among women with known risk 
factors for postpartum hemorrhage 
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4.0  METHODOLOGY 
4.1 Study Design 
This study was a randomized controlled single blinded study, which was conducted in 
Department of Obstetrics & Gynaecology, Hospital Raja Perempuan Zainab II Kota 
Bharu from December 2016 until April 2017. 
4.2 Study Setting   
Labour room, maternity operation theatre and obstetric ward at Department of 
Obstetrics & Gynaecology, Hospital Raja Perempuan Zainab II Kota Bharu with the 
collaboration of the consultants, specialists, medical officers, house officers and nursing 
staffs of the department. Hospital Raja Perempuan Zainab II (HRPZ II) is a government 
tertiary referral hospital, located in Kota Bharu town. The department of Obstetrics and 
Gynaecology was one of the earliest departments in HRPZII.  
 
The department has 1 labour suite equipped with 15 beds, 1 pregnancy assessment 
centre (PAC) which was equipped with 3 beds, 1 maternity theatre, 5 wards with 144 
beds with 1 specialist clinic. The total number of deliveries remained in the range of 
12,000 -13, 000 per year. 18.7% of patients were delivered via caesarean section. 
 
4.3 Study population 
All pregnant women who were planned for elective caesarean section as mode of 
delivery for this index pregnancy were assessed by the medical officer/ specialist/ 
consultant in charge in ward. Explanation regarding the research study was given for 
patients who fulfill the inclusion criteria. Patients who had understood the research 
study and consented were recruited as subjects for the study. 
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4.4 Inclusion Criteria and Exclusion Criteria 
4.4.1: Inclusion criteria  
• Women undergoing elective caesarean section under spinal anaesthesia.  
• Had at least 1 risk factor for PPH 
1. multiple pregnancy 
2. polyhydramnios 
3.  big baby  
4. obesity BMI>30 
5. grandmultipara (parity ≥5) 
6. severe preeclampsia 
7. previous lower segment caesarean scar  
8. history of PPH 
• Willing and able to give written consent. 
 
4.4.2: Exclusion criteria 
• Woman with any contraindication for the use of misoprostol or oxytocin and 
those with cardiovascular, hepatic or hematologic disorders.  
• Concomitant placenta previa or morbidly adherent placenta. 
 
4.5 Sample size determination 
Sample size for the study is calculated using the Power and Sample size (PS) software.  
α = 0.05, power= 0.8,   m = ratio of control to intervention group = 1:1 
δ = 100 ml; detectable mean difference of estimated blood loss(ml) in misoprostol 
group  and    control group  
σ = 201.5 ml; the standard deviation of blood loss(ml) in the Misoprostol group 
(chaudhuri, p.  2014) 
Total = 65 samples in each group. 
